Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
about
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskImprovement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.Association of the apolipoprotein b/apolipoprotein a-I ratio, metabolic syndrome components, total cholesterol, and low-density lipoprotein cholesterol with insulin resistance in the population of georgia.Assessing the Incremental Role of Novel and Emerging Risk Factors.The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study.Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intakeClinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance.Prediction of risk factors for coronary heart disease using Framingham Risk Score in Korean men.Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.Usefulness of insulin resistance estimation and the metabolic syndrome in predicting coronary atherosclerosis in type 2 diabetes mellitus.Assessing the value of risk predictions by using risk stratification tables.Dyslipidaemia in rheumatological autoimmune diseasesLDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone.The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratiosTamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapyAssociation of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samplesNon-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic populationUse of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.Spotlight on HDL-raising therapies: insights from the torcetrapib trials.Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites.Biomarkers of atherosclerosis: clinical applicationsLipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.Effects of the DASH-JUMP dietary intervention in Japanese participants with high-normal blood pressure and stage 1 hypertension: an open-label single-arm trial.2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review.Apolipoprotein measurements: is more widespread use clinically indicated?Lipid parameters for measuring risk of cardiovascular disease.Emerging options in the treatment of dyslipidemias: a bright future?Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study.The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population.Risk factors for hypertension in a population-based sample of postmenopausal women in Kolkata, West Bengal, India.Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial.Apolipoproteins and diabetic retinopathy.Predictors of the intima-media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients.Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function.Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
P2860
Q24626884-1B155E9A-1999-438E-9B2A-43D4A08E8ED5Q33436848-921BF2CE-2C6B-4F45-802C-85CBA8896F0BQ33572201-3F35377D-AB8A-4FA9-AB69-4BE751A60693Q33739964-CC3574AC-2E7F-4EDD-82E1-6A27FA87BAE8Q33995565-EE3886D8-1B89-46E8-9857-E753AC0DB0B7Q34142618-1649FD60-19C6-4591-8D6D-F8BC48DD0E5DQ34358061-8DF389B6-D483-487F-B46E-BD46234FC25BQ34403350-0AEC994C-9CAB-4C4A-BF75-8F97EC0DDCC8Q34427908-69DA2F76-636E-469A-9DFF-BD0464D7027DQ34568807-4EC2C3FB-B9DF-48B8-A846-B3ED02A3E58EQ34580155-ED29F2BB-ECAC-491F-9A63-A98D8073ADEDQ34969023-66DA7104-D20B-4F40-B7B4-D4DD05EAC11CQ35029916-4B27EB98-4917-4D29-B765-0B21B04F19BDQ35104699-23982E20-4C44-47FC-A589-16B76D1A99B4Q35234169-1C7D9478-654A-41AB-87FB-B50E3FCF945FQ35589699-9E15EAE0-D6FB-4E8D-8984-A5A9E33E00C7Q35913219-78C39294-CFA3-43EA-AFF7-E31B4DB805D1Q36318265-964745BF-1659-4DF6-9FC8-7537F4407AAFQ36384768-8413A431-5F63-47F2-9299-D5777406BEDDQ37041666-4633F61C-26DC-4833-A5CE-EFA6475A0A21Q37145837-FD1FDC5F-0368-47A0-8D4E-7EAD3613249AQ37267152-99A61A90-8E4E-4D11-BB6D-4B8429BA5D0DQ37307999-47676D64-02A0-4B59-843D-5B9F437A1D43Q37354657-07EC7B0F-DC9E-42B4-B994-A8F66F51823EQ37402396-B5C3B923-D8C0-4C9A-8752-80B28B0461DBQ37435149-63041C99-5F21-4473-A948-B5EFCEE0DACBQ37494202-CB62F3EA-7040-4D10-B2D5-512D4A03F868Q37594701-B0C337F3-D457-422C-9E7B-221DC2BAD839Q37833906-9660FA18-4335-41D2-ADAD-46EF1CF60CC4Q37842462-08268B0A-CDC0-4016-B9DD-733B50AB5A94Q37973386-CAC94EE2-C8AA-419E-80BC-D2B04B6D16FEQ39383777-598DEC7C-448D-4584-8E54-35EB4B529F7FQ39923045-6F21744A-4AA2-4CEF-A885-F205D5718224Q40097498-EE542C35-5045-407E-BD02-8402350D44DCQ41282919-E9A8AD45-87EF-4984-A5B2-DC8CC455C984Q42576522-15E6AFD8-2A52-4527-9084-29D44C549BC3Q42956278-64809D47-9079-4BB6-B0AC-64B126614FEAQ43043483-F6F9CA86-DA07-479A-976E-DFA8E1CBF87BQ43518850-0756E68B-B82A-429F-A2B4-4C566B7E8FB0Q44156647-CA8238FA-05FA-4AEF-B27C-6430AF1E0E89
P2860
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of the apolipoprotein B-a ...... trol analysis in EPIC-Norfolk.
@en
type
label
Role of the apolipoprotein B-a ...... trol analysis in EPIC-Norfolk.
@en
prefLabel
Role of the apolipoprotein B-a ...... trol analysis in EPIC-Norfolk.
@en
P2093
P50
P1476
Role of the apolipoprotein B-a ...... trol analysis in EPIC-Norfolk.
@en
P2093
Aeilko H Zwinderman
Erik S G Stroes
Evan A Stein
J Wouter Jukema
John J P Kastelein
Karim El-Harchaoui
Manjinder S Sandhu
S Matthijs Boekholdt
Wim A van der Steeg
P304
P356
10.7326/0003-4819-146-9-200705010-00007
P407
P577
2007-05-01T00:00:00Z